Theratechnologies’ (TSX:TH) presented results on HIV susceptibility to ibalizumab from a Phase 2b trial, along with new findings for EGRIFTA (tesamorelin for injection), at the 9th IAS Conference on HIV Science in Paris.
“HIV drug resistance is a key topic at the IAS conference this year, and these findings are particularly important as they suggest that ibalizumab is equally active against HIV whether it is resistant or responsive to approved anti-retroviral agents,” Steve Weinheimer, VP of biological sciences, at TaiMed Biologics USA, said in a statement.
“On the heels of the BLA acceptance for priority review, these data provide additional support for ibalizumab as a potential tool for the treatment of multidrug resistant HIV-1,” he added.
In a retrospective analysis of datasets from two placebo-controlled trials of EGRIFTA among HIV-infected adults with lipodystrophy, fat in trunk muscles decreased and trunk muscle area increased over 26 weeks in patients with excess visceral adipose tissue (VAT) who had shown a clinical response to EGRIFTA.
These results were seen across a number of trunk muscle groups and were independent of the change in amount of VAT for many of the measures. EGRIFTA is not indicated for trunk muscle fat decrease.
“This is the first study to evaluate changes in trunk muscle fat (both abdominal and spine musculature) in HIV patients who have responded to tesamorelin,” said Dr. Kristine Erlandson, MD, assistant professor of medicine, divisions of infectious disease and geriatric medicine, University of Colorado.
“We are pleased to continue to uncover new information on the potential effects of tesamorelin in HIV patients with excess abdominal fat,” she added.
